In 2024, Goldstein and Goldstein published results from an observational study of 21 men with various sexual dysfunctions (low libido, ED, trouble with orgasm, etc.) who were given subcutaneous bremelanotide to use as needed
The placebo group had a baseline weight of 73.1 1 kg and an end weight of 73.9 0.9 kg, while the NAC group had a baseline weight of 72.12 9.7 kg and an end weight of 72.12 4.6 kg
Available in 60-softgel size
Collectively, these results imply that the action of GLP-1R induced by GLP-1RAs cannot be attributed to one specific region of the brain but must be understood from a brain-wide perspective
As with other GLP-1 medicines, they are generally not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN2, and caution is needed in people with certain gastrointestinal issues, pancreatitis concerns, gallbladder disease, or other relevant medical conditions
PMID: 1102501